Aridis Pharmaceuticals, Inc. ARDS
0.00 USD 0.00 (+0.00%)
At closeNov 2, 2026, 4:00 PM EST
0.00145 Day range 0.00145
0.0001 52-week range 0.05
- YTD
- -86.67%
- 1 year
- -89.19%
Analyst view
Consensus: buy
Buy
Price target (mean) 10.00
Ratings (0m) 3 3 buy · 0 hold · 0 sell
- Strong buy0
- Buy3
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 3
- 1 month ago 3
- 2 months ago 3
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current year | -0.54 | -1.52 – 0.44 | -1.62 | +66.7% | 37.50M | +1113.2% | 2 |
| Next year | 0.26 | 0.26 – 0.26 | -0.54 | +148.1% | 41.41M | +10.4% | 1 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jan 26, 2023 | HC Wainwright & Co. | Maintained | — | Buy |
| Aug 16, 2022 | Maxim Group | Downgrade | Buy | Hold |
| Jul 20, 2021 | HC Wainwright & Co. | Maintained | — | Buy |
| May 15, 2020 | H.C. Wainwright | Reiterated | — | Buy |
| Feb 19, 2020 | Roth Capital | Initiated | — | Buy |
| Dec 30, 2019 | H.C. Wainwright | Initiated | — | Buy |
| Sep 10, 2018 | Northcoast Research | Initiated | — | Outperform |
| Sep 10, 2018 | Laidlaw & Co. | Initiated | — | Buy |
| Sep 10, 2018 | Cantor Fitzgerald | Initiated | — | Overweight |